» Articles » PMID: 28922543

In Vitro and in Vivo Degradation of Microfiber Bioresorbable Coronary Scaffold

Overview
Date 2017 Sep 19
PMID 28922543
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The degradation of Mirage Bioresorbable Microfiber Scaffold was evaluated in vitro and in vivo. The degradation in polymer molecular weight (MW), strut morphology, and integrity was accessed using gel permeation chromatography (GPC), X-ray micro-computed tomography (micro-CT) evaluation. To simulate the physiological degradation in vitro, scaffolds were deployed in silicone mock vessels connected to a peristaltic pumping system, which pumps 37°C phosphate-buffered saline (PBS, pH 7.4) at a constant rate. At various time points (30D, 60D, 90D, 180D, 270D, and 360D), the MW of microfibers decreased to 57.3, 49.8, 36.9, 13.9, 6.4, and 5.1% against the baseline. The in vivo degradation study was performed by implanting scaffolds in internal thoracic arteries (ITAs) of mini-swine. At the scheduled sacrifice time points (30D, 90D, 180D, 270D, 360D, and 540D), the implanted ITAs were excised for GPC analysis; the MW of the implanted scaffolds dropped to 58.5, 34.7, 24.8, 16.1, 12.9, and 7.1, respectively. Mass loss of scaffolds reached 72.4% at 540D of implantation. Two stages of hydrolysis were observed in in vitro and in vivo degradation kinetics, and the statistical analysis suggested a positive correlation between in vivo and in vitro degradation. After 6 months of incubation in animals, significant strut degradation was seen in the micro-CT evaluation in all sections as strut fragments and separations. The micro-CT results further confirmed that every sample at 720D had X-ray transmission similar to surrounding tissue, thereby indicating full degradation within 2 years. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 1842-1850, 2018.

Citing Articles

Bioresorbable Polymeric Scaffold in Cardiovascular Applications.

Toong D, Toh H, Ng J, Wong P, Leo H, Venkatraman S Int J Mol Sci. 2020; 21(10).

PMID: 32414114 PMC: 7279389. DOI: 10.3390/ijms21103444.


Preliminary design of a new degradable medical device to prevent the formation and recurrence of intrauterine adhesions.

Leprince S, Huberlant S, Allegre L, Warembourg S, Leteuff I, Bethry A Commun Biol. 2019; 2:196.

PMID: 31123719 PMC: 6531438. DOI: 10.1038/s42003-019-0447-x.


Performance of Polyester-Based Electrospun Scaffolds under In Vitro Hydrolytic Conditions: From Short-Term to Long-Term Applications.

Gil-Castell O, Badia J, Bou J, Ribes-Greus A Nanomaterials (Basel). 2019; 9(5).

PMID: 31121950 PMC: 6566282. DOI: 10.3390/nano9050786.


In vitro and in vivo degradation of microfiber bioresorbable coronary scaffold.

Huang C, Lee S, Horng S, Guy L, Yu T J Biomed Mater Res B Appl Biomater. 2017; 106(5):1842-1850.

PMID: 28922543 PMC: 6635671. DOI: 10.1002/jbm.b.33987.

References
1.
Huang C, Lee S, Horng S, Guy L, Yu T . In vitro and in vivo degradation of microfiber bioresorbable coronary scaffold. J Biomed Mater Res B Appl Biomater. 2017; 106(5):1842-1850. PMC: 6635671. DOI: 10.1002/jbm.b.33987. View

2.
Indolfi C, De Rosa S, Colombo A . Bioresorbable vascular scaffolds - basic concepts and clinical outcome. Nat Rev Cardiol. 2016; 13(12):719-729. DOI: 10.1038/nrcardio.2016.151. View

3.
Watling C, Lago N, Benmerah S, FitzGerald J, Tarte E, McMahon S . Novel use of X-ray micro computed tomography to image rat sciatic nerve and integration into scaffold. J Neurosci Methods. 2010; 188(1):39-44. DOI: 10.1016/j.jneumeth.2010.01.032. View

4.
Moses J, Leon M, Popma J, Fitzgerald P, Holmes D, OShaughnessy C . Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349(14):1315-23. DOI: 10.1056/NEJMoa035071. View

5.
Htay T, Liu M . Drug-eluting stent: a review and update. Vasc Health Risk Manag. 2007; 1(4):263-76. PMC: 1993957. DOI: 10.2147/vhrm.2005.1.4.263. View